Related Experiment Video
Updated: Dec 17, 2025

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
Published on: May 9, 2025
Three Novel COVID-19 Pneumonia Cases Successfully Treated With Lopinavir/Ritonavir
Tatsuhiko Wada1, Kosuke Shimode1, Takayuki Hoshiyama1,2
1Department of Rheumatology and Infectious Diseases, Kitasato University School of Medicine, Sagamihara, Japan.
Insights
Lopinavir/Ritonavir (LPV/r) effectively treated non-severe COVID-19 pneumonia in three elderly patients. This antiviral treatment offers a potential option for managing mild Coronavirus Disease 2019 cases.
Area of Science:
- Infectious Diseases
- Virology
- Pulmonology
Background:
- The global spread of Coronavirus Disease 2019 (COVID-19), caused by Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), necessitates effective treatment strategies.
- Early outbreaks included community transmission following a cruise ship incident in Japan.
Observation:
- Three patients admitted to Kitasato University Hospital presented with pneumonia.
- COVID-19 diagnosis was confirmed via real-time reverse transcriptase-polymerase chain reaction (RT-PCR) testing for SARS-CoV-2 nucleic acid.
- All patients were diagnosed with non-severe COVID-19 pneumonia.
Findings:
- Successful treatment of non-severe COVID-19 pneumonia was achieved using Lopinavir/Ritonavir (LPV/r).
- The treatment was effective even in elderly patients.
Implications:
- Lopinavir/Ritonavir (LPV/r) presents a viable therapeutic option for non-severe COVID-19 pneumonia.
- This finding is particularly relevant for managing mild cases in the elderly population.
Abstract:
Following the first case of Coronavirus Disease 2019 (COVID-19), caused by Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-Cov-2), in Wuhan, China, in December 2019, it has spread worldwide. An outbreak in Japan occurred on a cruise ship, and this was followed by community-acquired COVID-19. Herein, we report three cases of COVID-19 that presented pneumonia following admission to Kitasato University Hospital. Patients were admitted based on the positive result of real-time reverse transcriptase-polymerase chain reaction (RT-PCR) tests for COVID-19 nucleic acid. All patients were diagnosed as suffering from non-severe COVID-19 pneumonia and were successfully treated with Lopinavir/Ritonavir (LPV/r). LPV/r could be an option for treating non-severe COVID-19 pneumonia in general and even in elderly patients.
Related Concept Videos
Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Retrovirus Life Cycles
Pneumonia V: Nursing management and Prevention
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed....
Acute Respiratory Failure-III
Pneumonia III: Complications and Assessment
Pulmonary Tuberculosis IV
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...

